IP Library › Granted Patent US 11,713,354

Granted Patent B2

US 11,713,354 · App. 17/194,950 · Granted Aug 1, 2023

Galectin-10 antibodies

Inventors: Jean-Michel Percier (Ghent, BE); Christophe Blanchetot (Ghent, BE); Michael Saunders (Ghent, BE); Hans De Haard (Ghent, BE); Sebastian Van Der Woning (Ghent, BE); Emma Persson (Ghent, BE); Bart Lambrecht (Ghent, BE); Savvas Savvides (Ghent, BE); Hamida Hammad (Ghent, BE); Kenneth Verstraete (Ghent, BE)

Assignees: ARGENX BV; VIB VZW; Universiteit Gent

C07K16/2851 G01N33/68 A61K2039/505 C07K2317/55 C07K2317/622 G01N2333/4724

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,713,354
App. No.: 17/194,950
Granted: Aug 1, 2023
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Claims (193)

1. A method of inhibiting galectin-10 crystal formation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein the subject has a disease or condition selected from the group consisting of asthma; chronic rhinosinusitis; celiac disease; helminth infection; gastrointestinal eosinophilic inflammation; cystic fibrosis (CF); allergic bronchopulmonary aspergillosis (ABPA); Churg-Strauss vasculitis; chronic eosinophilic pneumonia; and acute myeloid leukemia, and wherein the antibody or antigen binding fragment thereof cross competes for binding to human galectin-10 with an antibody or antigen binding fragment thereof comprising a variable heavy chain domain (VH) and a variable light chain domain (VL) wherein the VH and VL domains comprise the CDR sequences selected from the group consisting of:

(i) HCDR3 comprising SEQ ID NO: 3, HCDR2 comprising SEQ ID NO: 2, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 58, LCDR2 comprising SEQ ID NO: 57, and LCDR1 comprising SEQ ID NO: 56;

(ii) HCDR3 comprising SEQ ID NO: 9, HCDR2 comprising SEQ ID NO: 8, HCDR1 comprising SEQ ID NO: 7, LCDR3 comprising SEQ ID NO: 64, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 62;

(iii) HCDR3 comprising SEQ ID NO: 12, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 10, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65;

(iv) HCDR3 comprising SEQ ID NO: 25, HCDR2 comprising SEQ ID NO: 24, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 77, and LCDR1 comprising SEQ ID NO: 76;

(v) HCDR3 comprising SEQ ID NO: 47, HCDR2 comprising SEQ ID NO: 46, HCDR1 comprising SEQ ID NO: 45, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71;

(vi) HCDR3 comprising SEQ ID NO: 43, HCDR2 comprising SEQ ID NO: 42, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 92;

(vii) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 44, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 97, LCDR2 comprising SEQ ID NO: 96, and LCDR1 comprising SEQ ID NO: 95;

(viii) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 52, HCDR1 comprising SEQ ID NO: 51, LCDR3 comprising SEQ ID NO: 98, LCDR2 comprising SEQ ID NO: 97, and LCDR1 comprising SEQ ID NO: 80;

(ix) HCDR3 comprising SEQ ID NO: 55, HCDR2 comprising SEQ ID NO: 54, HCDR1 comprising SEQ ID NO: 53, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71;

(x) HCDR3 comprising SEQ ID NO: 50, HCDR2 comprising SEQ ID NO: 49, HCDR1 comprising SEQ ID NO: 48, LCDR3 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 95;

(xi) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 5, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 61, LCDR2 comprising SEQ ID NO: 60, and LCDR1 comprising SEQ ID NO: 59;

(xii) HCDR3 comprising SEQ ID NO: 165, HCDR2 comprising SEQ ID NO: 164, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 182, LCDR2 comprising SEQ ID NO: 181, and LCDR1 comprising SEQ ID NO: 180;

(xiii) HCDR3 comprising SEQ ID NO: 174, HCDR2 comprising SEQ ID NO: 173, HCDR1 comprising SEQ ID NO: 172, LCDR3 comprising SEQ ID NO: 189, LCDR2 comprising SEQ ID NO: 188, and LCDR1 comprising SEQ ID NO: 180; and

(xiv) HCDR3 comprising SEQ ID NO: 165, HCDR2 comprising SEQ ID NO: 164, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 193, LCDR2 comprising SEQ ID NO: 181, and LCDR1 comprising SEQ ID NO: 180.

2. A method of inhibiting galectin-10 crystal formation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein:

(a) the antibody or antigen binding fragment thereof comprises a VH and a VL wherein the VH and VL domains comprise the CDR sequences selected from the group consisting of:

(i) HCDR3 comprising SEQ ID NO: 3, HCDR2 comprising SEQ ID NO: 2, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 58, LCDR2 comprising SEQ ID NO: 57, and LCDR1 comprising SEQ ID NO: 56;

(ii) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 5, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 61, LCDR2 comprising SEQ ID NO: 60, and LCDR1 comprising SEQ ID NO: 59;

(iii) HCDR3 comprising SEQ ID NO: 9, HCDR2 comprising SEQ ID NO: 8, HCDR1 comprising SEQ ID NO: 7, LCDR3 comprising SEQ ID NO: 64, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 62;

(iv) HCDR3 comprising SEQ ID NO: 12, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 10, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65;

(v) HCDR3 comprising SEQ ID NO: 15, HCDR2 comprising SEQ ID NO: 14, HCDR1 comprising SEQ ID NO: 13, LCDR3 comprising SEQ ID NO: 70, LCDR2 comprising SEQ ID NO: 69, and LCDR1 comprising SEQ ID NO: 68;

(vi) HCDR3 comprising SEQ ID NO: 18, HCDR2 comprising SEQ ID NO: 17, HCDR1 comprising SEQ ID NO: 16, LCDR3 comprising SEQ ID NO: 72, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 71;

(vii) HCDR3 comprising SEQ ID NO: 20, HCDR2 comprising SEQ ID NO: 19, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 75, LCDR2 comprising SEQ ID NO: 74, and LCDR1 comprising SEQ ID NO: 73;

(viii) HCDR3 comprising SEQ ID NO: 23, HCDR2 comprising SEQ ID NO: 22, HCDR1 comprising SEQ ID NO: 21, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65;

(ix) HCDR3 comprising SEQ ID NO: 25, HCDR2 comprising SEQ ID NO: 24, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 77, and LCDR1 comprising SEQ ID NO: 76;

(x) HCDR3 comprising SEQ ID NO: 28, HCDR2 comprising SEQ ID NO: 27, HCDR1 comprising SEQ ID NO: 26, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 79;

(xi) HCDR3 comprising SEQ ID NO: 31, HCDR2 comprising SEQ ID NO: 30, HCDR1 comprising SEQ ID NO: 29, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 80;

(xii) HCDR3 comprising SEQ ID NO: 33, HCDR2 comprising SEQ ID NO: 32, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 83, and LCDR1 comprising SEQ ID NO: 82;

(xiii) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 35, HCDR1 comprising SEQ ID NO: 34, LCDR3 comprising SEQ ID NO: 87, LCDR2 comprising SEQ ID NO: 86, and LCDR1 comprising SEQ ID NO: 85;

(xiv) HCDR3 comprising SEQ ID NO: 38, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 37, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 88;

(xv) HCDR3 comprising SEQ ID NO: 41, HCDR2 comprising SEQ ID NO: 40, HCDR1 comprising SEQ ID NO: 39, LCDR3 comprising SEQ ID NO: 91, LCDR2 comprising SEQ ID NO: 90, and LCDR1 comprising SEQ ID NO: 89;

(xvi) HCDR3 comprising SEQ ID NO: 43, HCDR2 comprising SEQ ID NO: 42, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 92;

(xvii) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 44, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 97, LCDR2 comprising SEQ ID NO: 96, and LCDR1 comprising SEQ ID NO: 95;

(xviii) HCDR3 comprising SEQ ID NO: 47, HCDR2 comprising SEQ ID NO: 46, HCDR1 comprising SEQ ID NO: 45, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71;

(xix) HCDR3 comprising SEQ ID NO: 50, HCDR2 comprising SEQ ID NO: 49, HCDR1 comprising SEQ ID NO: 48, LCDR3 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 95;

(xx) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 52, HCDR1 comprising SEQ ID NO: 51, LCDR3 comprising SEQ ID NO: 98, LCDR2 comprising SEQ ID NO: 97, and LCDR1 comprising SEQ ID NO: 80; and

(xxi) HCDR3 comprising SEQ ID NO: 55, HCDR2 comprising SEQ ID NO: 54, HCDR1 comprising SEQ ID NO: 53, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71;

(xxii) HCDR3 comprising SEQ ID NO: 162, HCDR2 comprising SEQ ID NO: 161, HCDR1 comprising SEQ ID NO: 160, LCDR3 comprising SEQ ID NO: 179, LCDR2 comprising SEQ ID NO: 178, and LCDR1 comprising SEQ ID NO: 177;

(xxiii) HCDR3 comprising SEQ ID NO: 165, HCDR2 comprising SEQ ID NO: 164, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 182, LCDR2 comprising SEQ ID NO: 181, and LCDR1 comprising SEQ ID NO: 180;

(xxiv) HCDR3 comprising SEQ ID NO: 168, HCDR2 comprising SEQ ID NO: 167, HCDR1 comprising SEQ ID NO: 166, LCDR3 comprising SEQ ID NO: 185, LCDR2 comprising SEQ ID NO: 184, and LCDR1 comprising SEQ ID NO: 183;

(xxv) HCDR3 comprising SEQ ID NO: 171, HCDR2 comprising SEQ ID NO: 170, HCDR1 comprising SEQ ID NO: 169, LCDR3 comprising SEQ ID NO: 187, LCDR2 comprising SEQ ID NO: 186, and LCDR1 comprising SEQ ID NO: 180;

(xxvi) HCDR3 comprising SEQ ID NO: 174, HCDR2 comprising SEQ ID NO: 173, HCDR1 comprising SEQ ID NO: 172, LCDR3 comprising SEQ ID NO: 189, LCDR2 comprising SEQ ID NO: 188, and LCDR1 comprising SEQ ID NO: 180;

(xxvii) HCDR3 comprising SEQ ID NO: 176, HCDR2 comprising SEQ ID NO: 175, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 192, LCDR2 comprising SEQ ID NO: 191, and LCDR1 comprising SEQ ID NO: 190; and

(xxviii) HCDR3 comprising SEQ ID NO: 165, HCDR2 comprising SEQ ID NO: 164, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 193, LCDR2 comprising SEQ ID NO: 181, and LCDR1 comprising SEQ ID NO: 180; or

(b) the antibody comprises a VHH domain comprising the CDR sequences selected from the group consisting of:

(i) CDR3 comprising SEQ ID NO: 210, CDR2 comprising SEQ ID NO: 209, and CDR1 comprising SEQ ID NO: 208;

(ii) CDR3 comprising SEQ ID NO: 213, CDR2 comprising SEQ ID NO: 212, and CDR1 comprising SEQ ID NO: 211;

(iii) CDR3 comprising SEQ ID NO: 216, CDR2 comprising SEQ ID NO: 215, and CDR1 comprising SEQ ID NO: 214;

(iv) CDR3 comprising SEQ ID NO: 219, CDR2 comprising SEQ ID NO: 218, and CDR1 comprising SEQ ID NO: 217;

(v) CDR3 comprising SEQ ID NO: 222, CDR2 comprising SEQ ID NO: 221, and CDR1 comprising SEQ ID NO: 220;

(vi) CDR3 comprising SEQ ID NO: 225, CDR2 comprising SEQ ID NO: 224, and CDR1 comprising SEQ ID NO: 223;

(vii) CDR3 comprising SEQ ID NO: 228, CDR2 comprising SEQ ID NO: 227, and CDR1 comprising SEQ ID NO: 226;

(viii) CDR3 comprising SEQ ID NO: 231, CDR2 comprising SEQ ID NO: 230, and CDR1 comprising SEQ ID NO: 229;

(ix) CDR3 comprising SEQ ID NO: 234, CDR2 comprising SEQ ID NO: 233, and CDR1 comprising SEQ ID NO: 232;

(x) CDR3 comprising SEQ ID NO: 236, CDR2 comprising SEQ ID NO: 235, and CDR1 comprising SEQ ID NO: 226;

(xi) CDR3 comprising SEQ ID NO: 238, CDR2 comprising SEQ ID NO: 237, and CDR1 comprising SEQ ID NO: 232;

(xii) CDR3 comprising SEQ ID NO: 241, CDR2 comprising SEQ ID NO: 240, and CDR1 comprising SEQ ID NO: 239;

(xiii) CDR3 comprising SEQ ID NO: 236, CDR2 comprising SEQ ID NO: 235, and CDR1 comprising SEQ ID NO: 226;

(xiv) CDR3 comprising SEQ ID NO: 244, CDR2 comprising SEQ ID NO: 243, and CDR1 comprising SEQ ID NO: 242;

(xv) CDR3 comprising SEQ ID NO: 234, CDR2 comprising SEQ ID NO: 233, and CDR1 comprising SEQ ID NO: 232;

(xvi) CDR3 comprising SEQ ID NO: 247, CDR2 comprising SEQ ID NO: 246, and CDR1 comprising SEQ ID NO: 245; and

(xvii) CDR3 comprising SEQ ID NO: 249, CDR2 comprising SEQ ID NO: 248, and CDR1 comprising SEQ ID NO: 217.

3. The method of claim 2 , wherein the antibody or antigen binding fragment thereof comprises a combination of a VH and a VL selected from the following:

(i) a VH comprising the amino acid sequence of SEQ ID NO: 99 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 100 or an amino acid sequence at least 90% identical thereto;

(ii) a VH comprising the amino acid sequence of SEQ ID NO: 101 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 102 or an amino acid sequence at least 90% identical thereto;

(iii) a VH comprising the amino acid sequence of SEQ ID NO: 103 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 104 or an amino acid sequence at least 90% identical thereto;

(iv) a VH comprising the amino acid sequence of SEQ ID NO: 105 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 106 or an amino acid sequence at least 90% identical thereto;

(v) a VH comprising the amino acid sequence of SEQ ID NO: 107 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 108 or an amino acid sequence at least 90% identical thereto;

(vi) a VH comprising the amino acid sequence of SEQ ID NO: 109 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 110 or an amino acid sequence at least 90% identical thereto;

(vii) a VH comprising the amino acid sequence of SEQ ID NO: 111 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 112 or an amino acid sequence at least 90% identical thereto;

(viii) a VH comprising the amino acid sequence of SEQ ID NO: 113 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 114 or an amino acid sequence at least 90% identical thereto;

(ix) a VH comprising the amino acid sequence of SEQ ID NO: 115 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 116 or an amino acid sequence at least 90% identical thereto;

(x) a VH comprising the amino acid sequence of SEQ ID NO: 117 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 118 or an amino acid sequence at least 90% identical thereto;

(xi) a VH comprising the amino acid sequence of SEQ ID NO: 119 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 120 or an amino acid sequence at least 90% identical thereto;

(xii) a VH comprising the amino acid sequence of SEQ ID NO: 121 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 122 or an amino acid sequence at least 90% identical thereto;

(xiii) a VH comprising the amino acid sequence of SEQ ID NO: 123 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 124 or an amino acid sequence at least 90% identical thereto;

(xiv) a VH comprising the amino acid sequence of SEQ ID NO: 125 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 126 or an amino acid sequence at least 90% identical thereto;

(xv) a VH comprising the amino acid sequence of SEQ ID NO: 127 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 128 or an amino acid sequence at least 90% identical thereto;

(xvi) a VH comprising the amino acid sequence of SEQ ID NO: 129 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 130 or an amino acid sequence at least 90% identical thereto;

(xvii) a VH comprising the amino acid sequence of SEQ ID NO: 131 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 132 or an amino acid sequence at least 90% identical thereto;

(xviii) a VH comprising the amino acid sequence of SEQ ID NO: 133 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 134 or an amino acid sequence at least 90% identical thereto;

(xix) a VH comprising the amino acid sequence of SEQ ID NO: 135 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 136 or an amino acid sequence at least 90% identical thereto;

(xx) a VH comprising the amino acid sequence of SEQ ID NO: 137 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 138 or an amino acid sequence at least 90% identical thereto;

(xxi) a VH comprising the amino acid sequence of SEQ ID NO: 139 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 140 or an amino acid sequence at least 90% identical thereto;

(xxii) a VH comprising the amino acid sequence of SEQ ID NO: 194 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 195 or an amino acid sequence at least 90% identical thereto;

(xxiii) a VH comprising the amino acid sequence of SEQ ID NO: 196 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 197 or an amino acid sequence at least 90% identical thereto;

(xxiv) a VH comprising the amino acid sequence of SEQ ID NO: 198 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 199 or an amino acid sequence at least 90% identical thereto;

(xxv) a VH comprising the amino acid sequence of SEQ ID NO: 200 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 201 or an amino acid sequence at least 90% identical thereto;

(xxvi) a VH comprising the amino acid sequence of SEQ ID NO: 202 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 203 or an amino acid sequence at least 90% identical thereto;

(xxvii) a VH comprising the amino acid sequence of SEQ ID NO: 204 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 205 or an amino acid sequence at least 90% identical thereto; and

(xxviii) a VH comprising the amino acid sequence of SEQ ID NO: 206 or an amino acid sequence at least 90% identical thereto and a VL comprising the amino acid sequence of SEQ ID NO: 207 or an amino acid sequence at least 90% identical thereto.

4. The method of claim 2 , wherein the antibody comprises a VHH domain and wherein the VHH domain comprises or consists of the amino acid sequence represented by any one of SEQ ID NOs: 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265 or 266, or an amino acid sequence at least 90% identical thereto.

5. A method of reducing the amount of galectin-10 crystals in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein the antibody or antigen binding fragment thereof cross competes for binding to human galectin-10 with an antibody or antigen binding fragment thereof comprising a variable heavy chain domain (VH) and a variable light chain domain (VL) wherein the VH and VL domains comprise the CDR sequences selected from the group consisting of: